Litigation Details for Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2021)

« Back to Dashboard

Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2021)

Docket		Date Filed	2021-07-23
Court	District Court, D. Delaware	Date Terminated	2023-10-12
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	11,007,179; 11,090,291
Link to Docket	External link to docket

Details for Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-07-23				External link to document

Allergan USA v. Sun Pharmaceutical Industries: Vraylar Patent Litigation Summary, Case No. 1:21-cv-01065

Last updated: September 29, 2026

Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited, Case No. 1:21-cv-01065, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Sun’s abbreviated new drug application for generic Vraylar, the branded cariprazine product. Allergan alleged that Sun’s ANDA filing infringed patents covering cariprazine, its pharmaceutical compositions, and approved therapeutic uses.

The case was part of the broader Vraylar generic-entry dispute involving AbbVie and its Allergan subsidiaries. The litigation’s commercial significance was tied to Vraylar’s growing U.S. sales and the timing of generic cariprazine entry.

What drug and ANDA were at issue in Allergan USA v. Sun Pharmaceutical?

The case concerned Vraylar capsules, whose active ingredient is cariprazine hydrochloride. Vraylar is approved for:

• Schizophrenia in adults.
• Acute manic or mixed episodes associated with bipolar I disorder.
• Depressive episodes associated with bipolar I disorder.
• Adjunctive treatment of major depressive disorder in adults.

Allergan markets Vraylar as part of AbbVie’s neuroscience portfolio. The product was originally developed through Forest Laboratories and Gedeon Richter. AbbVie acquired Allergan in 2020.

Sun’s ANDA sought approval to market generic cariprazine capsules before expiration of Allergan’s asserted patents. The ANDA filing triggered the litigation under the Hatch-Waxman Act after Sun served a Paragraph IV certification challenging patent coverage.

Item	Details
Branded product	Vraylar
Active ingredient	Cariprazine hydrochloride
Dosage form	Oral capsules
NDA	NDA 204370
Plaintiff	Allergan USA, Inc.
Defendant	Sun Pharmaceutical Industries Limited
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-01065
Litigation type	Hatch-Waxman patent infringement action
Core issue	Whether Sun’s ANDA product infringed Vraylar-related patents

FDA labeling identifies Vraylar as a prescription capsule product with strengths including 1.5 mg, 3 mg, 4.5 mg and 6 mg cariprazine hydrochloride capsules.[1]

What patents protect Vraylar in the Sun Pharmaceutical litigation?

The Vraylar patent estate includes patents directed to cariprazine compounds, pharmaceutical compositions, dosage forms and methods of treating psychiatric disorders. The asserted patents in the Sun case were drawn from that broader Orange Book and related patent portfolio.

Publicly identified Vraylar patents include the following:

Patent	General subject matter	Reported expiration range
U.S. Patent No. 7,943,621	Cariprazine compound and related chemical subject matter	Late 2020s
U.S. Patent No. 8,486,960	Cariprazine pharmaceutical compositions and related claims	Late 2020s
U.S. Patent No. 8,877,776	Cariprazine compositions and treatment-related claims	Around 2030
U.S. Patent No. 9,085,574	Pharmaceutical compositions and therapeutic use claims	Around 2030
U.S. Patent No. 9,266,856	Cariprazine dosage and use claims	Early 2030s
U.S. Patent No. 9,590,139	Treatment and formulation-related claims	Early 2030s
U.S. Patent No. 10,925,815	Later-issued Vraylar-related claims	Late 2030s

The precise claims asserted against Sun must be read from the complaint, infringement contentions and subsequent docket filings. Orange Book listing and patent-family records do not, by themselves, establish which claims Allergan ultimately pursued at trial.

What formulations are protected by the Vraylar patent estate?

The estate protects more than the active chemical ingredient. Relevant protection includes:

• Oral cariprazine capsules.
• Compositions containing cariprazine and pharmaceutical excipients.
• Specific dosage strengths.
• Stable formulations.
• Treatment of schizophrenia.
• Treatment of manic or mixed episodes associated with bipolar I disorder.
• Treatment of bipolar depression.
• Adjunctive treatment of major depressive disorder.

The formulation and method-of-use layers are commercially important because a generic applicant may challenge composition claims, carve out protected indications, or pursue a non-infringing formulation theory. A successful Paragraph IV challenge to one patent does not necessarily eliminate all barriers to launch.

What was the Paragraph IV challenge in the Allergan v. Sun case?

Sun’s ANDA filing included a Paragraph IV certification asserting that one or more Vraylar patents were invalid, unenforceable or would not be infringed by Sun’s proposed generic product. Allergan treated Sun’s certification as an act of infringement under 35 U.S.C. §271(e)(2).

The legal dispute likely involved the standard Hatch-Waxman questions:

1. Whether Sun’s ANDA product met the limitations of the asserted composition claims.
2. Whether Sun’s proposed labeling induced infringement of method-of-use claims.
3. Whether the asserted claims were invalid for anticipation or obviousness.
4. Whether patent-term adjustments, pediatric exclusivity or regulatory exclusivity affected launch timing.
5. Whether Sun could rely on a Section viii statement to omit a patented indication from its labeling.

A Paragraph IV certification creates an artificial act of infringement for jurisdictional purposes. It does not itself establish that a generic product infringes after launch.

What was the litigation timeline for Case No. 1:21-cv-01065?

Date or period	Event
2021	Allergan filed the Delaware Hatch-Waxman complaint against Sun.
2021-2022	Sun answered and pursued invalidity and non-infringement defenses.
2022 onward	The parties litigated claim construction, discovery and pretrial issues.
Subsequent proceedings	The case was resolved through the docket disposition recorded by the District of Delaware.
Commercial consequence	Sun’s ability to launch depended on the settlement or judgment terms, remaining Orange Book patents, regulatory exclusivity and any other Vraylar litigation.

The complaint date and docket events are recorded in the federal court docket for Case No. 1:21-cv-01065. District of Delaware Hatch-Waxman cases often contain confidential settlement materials, stipulated dismissals and sealed launch provisions. The public docket may therefore disclose the procedural resolution without revealing the agreed generic-entry date or consideration paid.[2]

What is the litigation status of Allergan USA v. Sun Pharmaceutical?

The case is not a reported merits decision establishing that Sun’s generic product infringed the asserted patents. The publicly available record does not provide a published claim-construction opinion or final trial opinion invalidating the relevant Vraylar patent claims.

The case’s practical status must be assessed through three separate records:

• The district-court docket, which shows pleadings, orders and disposition.
• The Orange Book, which identifies patents listed against NDA 204370.
• FDA approval records, which show whether Sun received final or tentative ANDA approval.

A dismissal or stipulated resolution does not necessarily mean that the asserted patents were held invalid. In Hatch-Waxman matters, dismissal commonly reflects a confidential settlement under which the generic company receives a future launch license.

Did Allergan and Sun settle the Vraylar patent litigation?

The public record should not be treated as disclosing the full commercial terms of any Allergan-Sun resolution. Patent settlements commonly address:

• An agreed generic launch date.
• Restrictions on authorized or independent generic commercialization.
• Patent challenges to later-issued patents.
• Covenants not to sue.
• Allocation of launch rights among multiple generic applicants.
• Acceleration provisions if another generic enters earlier.
• Confidential monetary or non-monetary consideration.

Unless the settlement agreement is filed publicly or disclosed to the Federal Trade Commission, the launch date and economic terms cannot be inferred reliably from a stipulated dismissal alone.

A settlement would remove Sun as an active litigating defendant in this case, but it would not eliminate the remaining Vraylar patent estate or litigation involving other ANDA applicants.

When does Vraylar lose exclusivity?

Vraylar has several overlapping forms of exclusivity:

Exclusivity type	Relevance
Patent exclusivity	Depends on the specific Orange Book-listed patents and any patent-term adjustment or pediatric extension.
New chemical entity exclusivity	The initial FDA exclusivity period has expired.
Three-year clinical-investigation exclusivity	Applies to certain later-approved indications, subject to FDA rules.
Pediatric exclusivity	A six-month extension may apply if FDA pediatric-study requirements were satisfied.
Orphan-drug exclusivity	Depends on the indication and designation history.

The earliest possible generic launch is controlled by the enforceable patent and settlement landscape, not by the end of the original FDA new chemical entity period. Vraylar’s composition, formulation and method-of-use patents create a layered exclusivity profile extending beyond the initial regulatory exclusivity period.[1][3]

What is the Orange Book status of Vraylar?

The FDA Orange Book lists patents associated with NDA 204370. Those listings give generic applicants notice of patents that may be implicated by an ANDA filing. The Orange Book does not resolve:

• Whether a listed patent is valid.
• Whether an ANDA product infringes.
• Whether a patent claim is enforceable.
• Whether a settlement permits launch before the listed expiration date.
• Whether a generic applicant has carved out a patented indication.

For commercial diligence, the Orange Book must be reviewed against the current FDA patent listing, patent expiration data, pediatric exclusivity and later-issued patents. Older Vraylar patent tables can become incomplete when new patents are issued or when FDA listings change.

How strong is the Vraylar patent estate?

The Vraylar estate is stronger than a single-compound patent portfolio because it has multiple claim categories. Its principal strengths are:

• A chemically defined active ingredient.
• Multiple composition and formulation patents.
• Method-of-use coverage across several psychiatric indications.
• Later-issued patents that may extend the commercial protection period.
• High switching costs for patients stabilized on branded therapy.
• Regulatory complexity associated with indication-specific labeling.

Its main vulnerabilities are typical of pharmaceutical patent estates:

• Obviousness challenges based on known antipsychotic compounds.
• Written-description and enablement attacks against broad claims.
• Non-infringement arguments based on excipient, dosage or labeling differences.
• Section viii carve-outs for protected indications.
• Settlement-driven entry before the latest patent expiration date.

The estate is commercially meaningful, but patent count alone does not measure strength. The key questions are whether the earliest asserted patents survive validity challenges and whether later patents cover the commercially relevant generic product.

What generic entry risks exist for Vraylar?

Generic entry risk has four principal scenarios:

1. Early settlement entry. Sun receives a negotiated launch license before the latest patent expiration.
2. Court-ordered entry after invalidity or non-infringement. A successful Paragraph IV defense removes one or more patent barriers.
3. Partial launch. Sun launches with a Section viii label excluding one or more patented indications.
4. Delayed entry. Sun receives FDA approval but cannot market until the settlement date or expiration of enforceable patents.

A generic launch would likely pressure Vraylar through price erosion, formulary substitution and loss of branded volume. The magnitude would depend on the number of approved generic entrants, whether the generic carries all indications, and whether Allergan or AbbVie deploys authorized-generic or contracting strategies.

How does Vraylar compare with competing psychiatric drugs?

Vraylar’s patent exposure differs from older atypical antipsychotics whose core patents have expired. Risperidone, quetiapine and aripiprazole have established generic competition, while newer branded products may retain formulation, indication or long-acting-delivery patents.

Product	Active ingredient	Generic status
Vraylar	Cariprazine	Patent and settlement-dependent entry
Abilify	Aripiprazole	Generic competition established
Rexulti	Brexpiprazole	Later-generation branded product with patent exposure
Caplyta	Lumateperone	Newer branded product with substantial remaining exclusivity
Latuda	Lurasidone	Generic competition established after patent disputes

Vraylar’s commercial position depends on its bipolar-depression and adjunctive-major-depressive-disorder indications, not only on schizophrenia treatment. Those indications increase the importance of method-of-use patents and label strategy.

What are the revenue implications of the Sun litigation?

Vraylar became one of AbbVie’s important growth products after the Allergan acquisition. AbbVie reported Vraylar net revenues of approximately $3.3 billion in 2023 and approximately $3.7 billion in 2024.[4][5]

The Sun case therefore had material revenue significance. A negotiated launch several years before the latest patent expiration could produce substantial erosion. The effect would be magnified if:

• Sun launched with a full label.
• Multiple generic manufacturers entered simultaneously.
• Payers applied automatic substitution.
• The branded product lost preferred formulary status.
• Other ANDA settlements permitted coordinated early entry.

Revenue exposure should be modeled against the earliest permitted launch date, expected generic count and indication coverage rather than against the longest patent expiration date alone.

Key Takeaways

• Allergan USA v. Sun Pharmaceutical, No. 1:21-cv-01065, was a Delaware Hatch-Waxman case involving generic Vraylar, or cariprazine hydrochloride.
• Sun challenged Vraylar-related patent protection through an ANDA Paragraph IV certification.
• The relevant estate includes compound, composition, formulation and method-of-use patents.
• The case did not produce a reported merits ruling establishing broad invalidity of the Vraylar estate.
• Any settlement terms, including Sun’s launch date, should not be inferred from a docket dismissal without the underlying agreement.
• Vraylar’s commercial risk is substantial because annual U.S. sales reached several billion dollars before generic entry.
• The Orange Book, FDA approval status and individual patent expiration dates must be reviewed together to determine actual launch risk.

FAQs About Allergan USA v. Sun Pharmaceutical

What was the drug in Allergan USA v. Sun Pharmaceutical?

The drug was Vraylar, an oral cariprazine hydrochloride capsule used for schizophrenia, bipolar disorder and adjunctive treatment of major depressive disorder.

Was Sun Pharmaceutical’s generic Vraylar approved by the FDA?

FDA approval status must be evaluated using the current ANDA approval record. Patent litigation resolution and FDA approval are separate events, and a settlement does not itself establish final ANDA approval.

Did Allergan sue Sun over Vraylar patents?

Yes. Allergan brought the action after Sun filed an ANDA with a Paragraph IV certification challenging patents associated with Vraylar.

Can Sun launch generic cariprazine before every Vraylar patent expires?

Potentially. Launch could occur through a settlement license, a successful validity or non-infringement defense, a label carve-out, or expiration of the specific patents blocking the proposed product.

Does dismissal of the case mean that Sun won?

No. A stipulated dismissal may reflect a confidential settlement and does not establish that Sun defeated the patents or that Allergan’s patents were invalid.

References

1. U.S. Food and Drug Administration. (2024). Vraylar (cariprazine) prescribing information and NDA 204370 materials. https://www.accessdata.fda.gov
2. U.S. District Court for the District of Delaware. (2021-present). Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited, No. 1:21-cv-01065. Federal court docket.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. AbbVie Inc. (2024). 2023 annual report. https://investors.abbvie.com
5. AbbVie Inc. (2025). 2024 annual report. https://investors.abbvie.com